Gilead Sciences to Expand Liver Disease Pipeline with Biotech CymaBay Therapeutics Buy
- February 16, 2024
Gilead Sciences, Inc. announced February 12 a deal to acquire biotech CymaBay Therapeutics and its leading product candidate, seladelpar, for treating primary biliary cholangitis (PBC), a rare and chronic liver disease that mainly affects women.
ARTICLE TAGS
You must be logged in to access this content.